Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;10(12):6407-6411.
doi: 10.21037/jtd.2018.12.01.

Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?

Megan Greally  1 , Geoffrey Y Ku  1
Affiliations
Editorial

Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?

Megan Greally et al. J Thorac Dis. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: GY Ku reports research grants from Aduro Biotech, Arog Pharmaceuticals, Astra-Zeneca, Bristol-Myers Squibb, Merck and Pieris; and consulting for Bristol-Myers Squibb, Eli Lilly, Merck and Pieris. The other author has no conflicts of interest to declare.

Comment on

References

    1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461-71. 10.1016/S0140-6736(17)31827-5 - DOI - PubMed
    1. Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013. 10.1001/jamaoncol.2018.0013 - DOI - PMC - PubMed
    1. Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol 2018;36:2836-44. 10.1200/JCO.2017.76.6212 - DOI - PMC - PubMed
    1. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol 2018;29:2052-60. 10.1093/annonc/mdy264 - DOI - PMC - PubMed
    1. Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123-33. 10.1016/S0140-6736(18)31257-1 - DOI - PubMed